Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qlaira vs Microgynon for Hormone Withdrawal Symptoms
NCT00778609Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of estradiol valerate + dienogest in contraception, dysmenorrhea and menstrual migraine (2 arms), sponsored by Bayer. Primary endpoint: Change in frequency and intensity of hormone withdrawal associated symptoms headache and pelvic pain at Cycle 6. Started Dec 2008; status: completed.
02
Drugs
estradiol valerate + dienogest
03
Conditions
contraceptiondysmenorrheamenstrual migraine
Beyond the preview
Go deeper on NCT00778609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00778609.